개 관절염 시장 : 제품 유형, 투여 경로, 최종사용자, 치료 유형별 - 세계 예측(2025-2030년)

The Canine Arthritis Market was valued at USD 1.81 billion in 2023, expected to reach USD 1.92 billion in 2024, and is projected to grow at a CAGR of 7.88%, to USD 3.08 billion by 2030.

Canine arthritis, a degenerative joint disease, primarily affects the cartilage in dogs, leading to pain, stiffness, and impaired movement. As the prevalence of arthritis in dogs rises, driven by factors such as increasing pet ownership and a growing population of aged dogs, the market for canine arthritis treatment and management is expanding significantly. The necessity for effective arthritis treatments in dogs is undeniable, primarily due to the enhanced understanding of pet welfare and the increasing trend towards humanizing pet healthcare. Applications for arthritis management range from pharmaceutical interventions, such as non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying osteoarthritis drugs (DMOADs), to non-pharmaceutical therapies like physiotherapy, acupuncture, and dietary supplements. The end-use scope involves veterinary clinics, pet hospitals, and even in-home care solutions provided by pet owners who wish to maintain their pets' quality of life. Key growth influencers are advancements in veterinary medicine that provide newer, more effective treatments, and heightened awareness among pet owners about arthritis symptoms and treatment options. Meanwhile, untapped opportunities reside in the development of innovative, minimally invasive treatment techniques and the proliferation of natural or holistic treatment options, aligning with consumer preferences for organic and natural health solutions for their pets. Nonetheless, the market's growth is curtailed by challenges such as high costs associated with advanced treatments, lack of insurance coverage for pets, and insufficient awareness in developing regions. Areas ripe for innovation include enhanced diagnostic tools for early detection and personalized treatment plans based on individual genetic profiles. The nature of the canine arthritis market is dynamic, characterized by rapid advancements in veterinary science and an increasingly informed consumer base, suggesting that businesses should focus not just on treatment efficacy but also on educating consumers and broadening accessibility to drive growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Canine Arthritis Market

The Canine Arthritis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of arthritis among the global canine population due to aging pets and lifestyle
  • Innovations in veterinary medicine and treatments for managing canine arthritis effectively
  • Growing awareness and pet owner's willingness to spend on canine health and wellness
  • Advancements in diagnostic techniques leading to early detection and treatment of arthritis in dogs
• Market Restraints
  • Insufficient number of specialized veterinary professionals to adequately address canine arthritis cases
  • Regulatory challenges affecting the approval and availability of novel treatments for canine arthritis
• Market Opportunities
  • Specialized canine arthritis treatment centers offering holistic and integrative medical approaches
  • Subscription-based delivery of joint supplements and pain relief medications for arthritic dogs
  • Wearable technology for continuous monitoring and management of arthritis symptoms in dogs
• Market Challenges
  • High costs associated with veterinary care and arthritis treatments leading to reduced market accessibility
  • Lack of awareness and education among pet owners about early signs and preventive care for canine arthritis

Porter's Five Forces: A Strategic Tool for Navigating the Canine Arthritis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Canine Arthritis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Canine Arthritis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Canine Arthritis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Canine Arthritis Market

A detailed market share analysis in the Canine Arthritis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Canine Arthritis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Canine Arthritis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Canine Arthritis Market

A strategic analysis of the Canine Arthritis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Canine Arthritis Market, highlighting leading vendors and their innovative profiles. These include Bayer AG, Boehringer Ingelheim International GmbH, Ceva Sante Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health Incorporated, Merck Animal Health, Nutramax Laboratories, Inc., Vetoquinol S.A., Virbac, and Zoetis Inc..

Market Segmentation & Coverage

This research report categorizes the Canine Arthritis Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product Type, market is studied across Assistive Devices and Joint Support, Disease-Modifying Osteoarthritis Drugs (DMOADs), Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Pain Management Drugs, and Surgical Treatments. The Assistive Devices and Joint Support is further studied across Braces, Harnesses, and Other Assistive Devices. The Disease-Modifying Osteoarthritis Drugs (DMOADs) is further studied across Structure-Modifying DMOADs and Symptomatic DMOADs. The Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is further studied across Over-the-Counter NSAIDs and Prescription NSAIDs. The Pain Management Drugs is further studied across Opioids, Other Pain Management Drugs, and Steroids. The Surgical Treatments is further studied across Arthroscopic Surgery, Joint Replacement Surgery, and Other Surgical Treatments.
• Based on Route of Administration, market is studied across Injectable, Oral, and Topical.
• Based on End User, market is studied across Online Pharmacies, Retail Pharmacies, and Veterinary Hospitals and Clinics.
• Based on Therapy Type, market is studied across Drug Therapy, Physical Therapy, and Surgical Therapy. The Physical Therapy is further studied across Acupuncture, Hydrotherapy, Laser Therapy, and Other Physical Therapies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of arthritis among the global canine population due to aging pets and lifestyle
    • 5.1.1.2. Innovations in veterinary medicine and treatments for managing canine arthritis effectively
    • 5.1.1.3. Growing awareness and pet owner's willingness to spend on canine health and wellness
    • 5.1.1.4. Advancements in diagnostic techniques leading to early detection and treatment of arthritis in dogs
  • 5.1.2. Restraints
    • 5.1.2.1. Insufficient number of specialized veterinary professionals to adequately address canine arthritis cases
    • 5.1.2.2. Regulatory challenges affecting the approval and availability of novel treatments for canine arthritis
  • 5.1.3. Opportunities
    • 5.1.3.1. Specialized canine arthritis treatment centers offering holistic and integrative medical approaches
    • 5.1.3.2. Subscription-based delivery of joint supplements and pain relief medications for arthritic dogs
    • 5.1.3.3. Wearable technology for continuous monitoring and management of arthritis symptoms in dogs
  • 5.1.4. Challenges
    • 5.1.4.1. High costs associated with veterinary care and arthritis treatments leading to reduced market accessibility
    • 5.1.4.2. Lack of awareness and education among pet owners about early signs and preventive care for canine arthritis
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Canine Arthritis Market, by Product Type

• 6.1. Introduction
• 6.2. Assistive Devices and Joint Support
  • 6.2.1. Braces
  • 6.2.2. Harnesses
  • 6.2.3. Other Assistive Devices
• 6.3. Disease-Modifying Osteoarthritis Drugs (DMOADs)
  • 6.3.1. Structure-Modifying DMOADs
  • 6.3.2. Symptomatic DMOADs
• 6.4. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • 6.4.1. Over-the-Counter NSAIDs
  • 6.4.2. Prescription NSAIDs
• 6.5. Pain Management Drugs
  • 6.5.1. Opioids
  • 6.5.2. Other Pain Management Drugs
  • 6.5.3. Steroids
• 6.6. Surgical Treatments
  • 6.6.1. Arthroscopic Surgery
  • 6.6.2. Joint Replacement Surgery
  • 6.6.3. Other Surgical Treatments

7. Canine Arthritis Market, by Route of Administration

• 7.1. Introduction
• 7.2. Injectable
• 7.3. Oral
• 7.4. Topical

8. Canine Arthritis Market, by End User

• 8.1. Introduction
• 8.2. Online Pharmacies
• 8.3. Retail Pharmacies
• 8.4. Veterinary Hospitals and Clinics

9. Canine Arthritis Market, by Therapy Type

• 9.1. Introduction
• 9.2. Drug Therapy
• 9.3. Physical Therapy
  • 9.3.1. Acupuncture
  • 9.3.2. Hydrotherapy
  • 9.3.3. Laser Therapy
  • 9.3.4. Other Physical Therapies
• 9.4. Surgical Therapy

10. Americas Canine Arthritis Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Canine Arthritis Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Canine Arthritis Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Bayer AG
• 2. Boehringer Ingelheim International GmbH
• 3. Ceva Sante Animale
• 4. Dechra Pharmaceuticals PLC
• 5. Elanco Animal Health Incorporated
• 6. Merck Animal Health
• 7. Nutramax Laboratories, Inc.
• 8. Vetoquinol S.A.
• 9. Virbac
• 10. Zoetis Inc.